迟发性运动障碍
医学
吡拉西坦
药理学
加巴喷丁
药品
左乙拉西坦
运动障碍
氯硝西泮
癫痫
内科学
精神科
精神分裂症(面向对象编程)
替代医学
病理
疾病
帕金森病
出处
期刊:Journal of Psychosocial Nursing and Mental Health Services
[SLACK, Inc.]
日期:2011-06-13
卷期号:49 (7): 17-20
被引量:14
标识
DOI:10.3928/02793695-20110602-02
摘要
Tardive dyskinesia (TD) is a serious complication associated with the long-term use of dopamine receptor-blocking drugs. No drugs are approved by the U.S. Food and Drug Administration for treating TD. A number of drugs appear to have some benefit for its treatment, including branched-chain amino acids, piracetam (Nootropil ® , Nootrop ® , Nootropyl ® ), clonazepam (Klonopin ® ), levetiracetam (Keppra ® ), propranolol (Inderal ® ), and clonidine (Catapres ® ), and they would be clinically reasonable to try. Gabapentin (Neurontin ® and others) has a good safety profile and would be appropriate to consider, although no controlled trials confirm its efficacy. The efficacy of ginkgo biloba should be balanced against its safety concerns. Essential fatty acids have not been shown to be effective. Antioxidant therapies, including vitamin E, melatonin, and vitamin B 6 , could conceivably be used together with other drug therapies for the treatment of TD.
科研通智能强力驱动
Strongly Powered by AbleSci AI